Assess whether labeling language overclaims the evidence (cdc1b2)

Situation

The desk packet is disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• 505(b)(2) development lead can defend Proceed under protocol from disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge.
• 505(b)(2) development lead cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design.
• A pediatric ethicist objecting to the proposed design never reached the population in disproportionate reporting signal workbook — reopen intake, do not close labeling language overclaims the.
• Two facts in disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a pediatric ethicist objecting to the proposed design and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.